期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

骨关节炎关节软骨细胞外基质降解靶点的研究进展 被引量：4

Research advance in extracellular cell matrix degradation targets in articular cartilage with osteoarthritis
原文传递
导出
摘要 骨关节炎潜在的发病机制和软骨不可逆转的损伤机制尚不明确,目前尚无有效改善骨关节炎病情的药物。本文简要概述细胞外基质降解相关作用靶点,为新药开发提供参考。 Osteoarthritis （OA） is an age-related disease and the leading cause of pain and disability, which is characterized by chronic degeneration of articular cartilage. The underlying causes of disease initiation and progression to irreversible cartilage destruction are still unknown. There is currently no effective disease-modifying OA drug （DMOAD）. This review mainly summarizes the recent discoveries in regard to the degradation of extracellular cell matrix in articular cartilage.
作者 刘艺 沈龙海
机构地区 上海医药工业研究院药理评价研究中心
出处 《世界临床药物》 CAS 2015年第5期353-357,共5页 World Clinical Drug
关键词 骨关节炎(OA) 基质金属蛋白酶(MMP) 聚蛋白聚糖酶 成纤维细胞生长因子(FGF) 骨形态发生蛋白(BMP) 生长分化因子-5(GDF-5) 脂肪因子 osteoarthritis （OA） matrix metalloproteinase （MMPs） ADAMTS fibroblastgrowth factor （FGF） bone morphogenetic protein （BMP） growth differentiation factor-5 （GDF-5） adipokines
分类号 R966 [医药卫生—药理学] R365 [医药卫生—病理学]
  • 相关文献

参考文献32

  • 1WHO scientific group on the Burden of Millenniumconditions at the Start of the New Millennium. The burden of muscu- loskeletal conditions at the start of the new millennium [J]. World Health Organ Tech Rep Ser, 2003, 919:i-x,l-218,back caver.
  • 2Freemont AJ, Hampson V, Tilman R, et al. Gene expression of matrix metalloproteinases 1, 3, and 9 by chondrocytes in osteoarthritic human knee articular cartilage is zone and grade specific [J]. Ann Rheum Dis, 1997, 56 (9) : 542-549.
  • 3Buhrmann C, Mobasheri A, Marls U, et al. Curcumin mediated suppression of nuclear factor-~B promotes chondrogenic differentiation of mesenehymal stem cells in a high-density co- culture microenvironment [Jl. Arthritis Res Ther, 2010, 12 (4): R127.
  • 4Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology[J]. Biorheology, 2002, 39 (1-2) : 237-246.
  • 5Baragi VM, Becher G, Bendele AM, et al. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models [J]. Arthritis Rheum, 2009, 60 (7) : 2008-2018.
  • 6Settle S, Vickery L, Nemirovskiy O, et al. Cartilage degradation biomarkers predict efficacy of a novel, highly selective matrix metalloproteinase 13 inhibitor in a dog model of osteoarthritis: confirmation by multivariate analysis that modulation of type II collagen and aggrecan degradation peptides parallels pathologic changes [Jl. Arthritis Rheum, 2010, 52 (10) : 3005-3015.
  • 7Durigova M, Nagase H, Mort JS, et al. MMPs are less efficient than ADAMTS5 in cleaving aggrecan core proteinEJj. Matrix Biol, 2011, 30(2): 145-153.
  • 8Chu X, You H, Yuan X, et al. Protective effect of lentivirus- mediated siRNA targeting ADAMTS-5 on cartilage degradation in a rat model of osteoarthritis [J]. Int Mol Med, 2013, 31 (5): 1222-1228.
  • 9Hashimoto G, Aoki T, Nakamura H, et al. Inhibition ofADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4) [J]. FEBS Lett, 494 (2001) : 192-195.
  • 10Kashiwagi M, Tortorella M, Nagase H, et al. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) andaggrecanase 2 (ADAM-TS5) [J]. Biol Chem, 2001, 494 (3): 12501-12504.

同被引文献52

引证文献4

二级引证文献3

世界临床药物
2015年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部